信達生物-B(01801.KH)抗癌藥物達攸同獲國家藥監局上市批准
信達生物-B(01801.KH)公布,公司自主研發的重組人源化抗血管內皮生長因子(VEGF)單克隆抗體藥物達攸同獲國家藥品監督管理局上市批准,用於在中國治療晚期非小細胞肺癌和轉移性結直腸癌患者。
達攸同是繼達伯舒之後,信達生物第二個獲得國家藥監局上市批准的單克隆抗體藥物。
達攸同為貝伐珠單抗注射液生物類似藥,又名重組抗VEGF人源化單克隆抗體注射液,其阻斷腫瘤組織的血液供應,抑制腫瘤細胞的增殖和轉移,誘導腫瘤細胞凋亡,從而達到抗腫瘤的治療效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.